Approaches to Enhance the Efficacy of DNA Vaccines

Critical Reviews in Clinical Laboratory Sciences

Volumn 41, Issue 1, 2004, Pages 1-39

  Manoj, Sharmila ^a,b,c   Babiuk, Lome A ^a   Van Drunen Littel van Den Hurk, Sylvia ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Animal models; DNA immunization; DNA vaccines; Immune responses; Plasmids; Strategies; Vaccine delivery; Vaccine efficacy

Indexed keywords

AURINTRICARBOXYLIC ACID; CHOLERA TOXIN; CYTOKINE; DNA VACCINE; LYMPHOTOXIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CELLULAR DISTRIBUTION; CODON; CPG ISLAND; DNA SHUFFLING; DRUG EFFICACY; GENE DELIVERY SYSTEM; GENETIC TRANSCRIPTION; HOST; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TH2 CELL; TRANSGENE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; HUMANS; IMMUNITY; MODELS, ANIMAL; PLASMIDS; TREATMENT OUTCOME; VACCINES, DNA;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 1542284212     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360490269251     Document Type: Review

References (235)

1. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
2. Tang DC, De Vit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
3. Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 1993; 67: 5664-7.
4. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
5. Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48.
6. Van Drunen Littel-van den Hurk S, Braun RP, Lewis PJ, et al. Immunization of neonates with DNA encoding a bovine herpesvirus glycoprotein is effective in the presence of maternal antibodies. Viral Immunol 1999; 12: 67-77.
7. Lewis PJ, van Drunen Littel-Van Den H, Babiuk LA. Induction of immune responses to bovine herpesvirus type 1 gD in passively immune mice after immunization with a DNA-based vaccine. J Gen Virol 1999; 80: 2829-37.
8. Liu MA, McClements W, Ulmer JB, et al. Immunization of non-human primates with DNA vaccines. Vaccine 1997; 15: 909-12.
9. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002; 2: 183-94.
10. Wattiaux R, Laurent N, Wattiaux-De Coninck S, et al. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000; 41: 201-8.
11. Johnston S, Talaat A, McGuire M. Genetic Immunization. What's in a Name? Arch Med Res 2002; 33: 325.
12. van Drunen Littel-van den Hurk S, Gerdts V, Loehr BI, et al. Recent advances in the use of DNA vaccines for the treatment of diseases of farmed animals. Adv Drug Deliv Rev 2000; 43: 13-28.
13. Dupuis M, Denis-Mize K, Woo C, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000; 165: 2850-8.
14. Kerr IM, Stark GR. The antiviral effects of the interferons and their inhibition. J Interferon Res 1992; 12: 237-40.
15. Harms JS, Oliveira SC, Splitter GA. Regulation of transgene expression in genetic immunization. Braz J Med Biol Res 1999; 32: 155-62.
16. Lee AH, Suh YS, Sung JH, et al. Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol Cells 1997; 7: 495-501.
17. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16: 174-81.
18. Gebhard JR, Zhu J, Cao X, et al. DNA immunization utilizing a herpes simplex virus type 2 myogenic DNA vaccine protects mice from mortality and prevents genital herpes. Vaccine 2000; 18: 1837-46.
19. Bojak A, Hammer D, Wolf H, et al. Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis. Vaccine 2002; 20: 1975-9.
20. Loirat D, Li Z, Mancini M, et al. Muscle-specific expression of hepatitis B surface antigen: no effect on DNA-raised immune responses. Virology 1999; 260: 74-83.
21. Weeratna RD, Wu T, Efler SM, et al. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther 2001; 8: 1872-8.
22. Tomoe J, Kusk P, Johansen T, et al. Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites. Gene 2002; 297: 21.
23. Saier MH, Jr. Differential codon usage: a safeguard against inappropriate expression of specialized genes? FEBS Lett 1995; 362: 1-4.
24. Kurland CG. Codon bias and gene expression. FEBS Lett 1991; 285: 165-9.
25. Andersson SG, Kurland CG. Codon preferences in free-living microorganisms. Microbiol Rev 1990; 54: 198-210.
26. Holm L. Codon usage and gene expression. Nucleic Acids Res 1986; 14: 3075-87.
27. Stratford R, Douce G, Zhang-Barber L, et al. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine 2000; 19: 810-5.
28. Liu WJ, Zhao KN, Gao FG, et al. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001; 20: 862-9.
29. Liu WJ, Gao F, Zhao KN, et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 2002; 301: 43-52.
30. Demi L, Bojak A, Steck S, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001; 75: 10991-1001.
31. zur Megede J, Chen MC, Doe B, et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74: 2628-35.
32. Vinner L, Nielsen HV, Bryder K, et al. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine 1999; 17: 2166-75.
33. Narum DL, Kumar S, Rogers WO, et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 2001; 69: 7250-3.
34. Nagata T, Uchijima M, Yoshida A, et al. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 1999; 261: 445-51.
35. Uchijima M, Yoshida A, Nagata T, et al. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998; 161: 5594-9.
36. Karlin S, Mrazek J, Campbell AM. Codon usages in different gene classes of the Escherichia coli genome. Mol Microbiol 1998; 29: 1341-55.
37. Jenkins GM, Pagel M, Gould EA, et al. Evolution of base composition and codon usage bias in the genus Flavivirus. J Mol Evol 2001; 52: 383-90.
38. Wu LF, Saier MH, Jr. Differences in codon usage among genes encoding proteins of different function in Rhodobacter capsulatus. Res Microbiol 1991; 142: 943-9.
39. Kwissa M, Unsinger J, Schirmbeck R, et al. Polyvalent DNA vaccines with bidirectional promoters. J Mol Med 2000; 78: 495-506.
40. Kamiya H, Yamazaki J, Harashima H. Size and topology of exogenous DNA as determinant factors of transgene transcription in mammalian cells. Gene Ther 2002; 9: 1500-7.
41. Mizuguchi H, Xu Z, Ishii-Watabe A, et al. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1: 376-82.
42. Wild J, Gruner B, Metzger K, et al. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid. Vaccine 1998; 16: 353-60.
43. Manoj S, Babiuk LA, van Drunen Littel-van den Hurk S. Immunization with a dicistronic plasmid expressing a truncated form of bovine herpesvirus-1 glycoprotein D and the amino terminal subunit of glycoprotein B results in reduced gB-specific immune responses. Virology in press.
44. O'Hagan D, Singh M, Ugozzoli M, et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75: 9037-43.
45. Jin J, Yang JY, Liu J, et al. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World J Gastroenterol 2002; 8: 505-10.
46. Gerloni M, Xiong S, Mukerjee S, et al. Functional cooperation between T helper cell determinants. Proc Natl Acad Sci USA 2000; 97: 13269-74.
47. Patten PA, Howard RJ, Stemmer WP. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr Opin Biotechnol 1997; 8: 724-33.
48. Osen W, Peiler T, Ohlschlager P, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001; 19: 4276-86.
49. Braun R, Babiuk LA, van Drunen Littel-van den H. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 1998; 79: 2965-70.
50. Collings A, Pitkanen J, Strengell M, et al. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunized with non-replicating or self-replicating expression vectors. Vaccine 1999; 18: 460-7.
51. Herrera AM, Rodriguez EG, Hernandez T, et al. A family of compact plasmid vectors for DNA immunization in humans. Biochem Biophys Res Commun 2000; 279: 548-51.
52. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-4.
53. Pontarollo RA, Babiuk LA, Hecker R, et al. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 2002; 83: 2973-81.
54. Panayotatos N. Recombinant protein production with minimal-antibiotic- resistance vectors. Gene 1988; 74: 357-63.
55. Williams SG, Cranenburgh RM, Weiss AM, et al. Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 1998; 26: 2120-4.
56. Cranenburgh RM, Hanak JA, Williams SG, et al. Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 2001; 29: E26.
57. Schakowski F, Gorschluter M, Junghans C, et al. A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 2001; 3: 793-800.
58. Zhang EP, Muller A, Schulte F, et al. Minimizing side effects of ballistic gene transfer into the murine comeal epithelium. Graefes Arch Clin Exp Ophthalmol 2002; 240: 114-9.
59. Boretti FS, Leutenegger CM, Mislin C, et al. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 2000; 14: 1749-57.
60. Leutenegger CM, Boretti FS, Mislin CN, et al. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J Virol 2000; 74: 10447-57.
61. Muller A, Zhang EP, Schroff M, et al. Influence of ballistic gene transfer on antigen-presenting cells in murine corneas. Graefes Arch Clin Exp Ophthalmol 2002; 240: 851-9.
62. Konig Merediz SA, Zhang EP, Wittig B, et al. Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the comeal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000; 238: 701-7.
63. Schirmbeck R, Konig-Merediz SA, Riedl P, et al. Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J Mol Med 2001; 79: 343-50.
64. Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91: 295-8.
65. Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol 2002; 3: REVIEWS3011.
66. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
67. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98: 9237-42.
68. Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-31.
69. Lipford GB, Bauer M, Blank C, et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997; 27: 2340-4.
70. Carson DA, Raz E. Oligonucleotide adjuvants for T helper 1 (Th1) -specific vaccination. J Exp Med 1997; 186: 1621-2.
71. Weiss R, Scheiblhofer S, Freund J, et al. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002; 20: 3148.
72. Jackson LA, Austin G, Chen RT, et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001; 19: 4703-9.
73. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18: 3964-73.
74. Williams J, Fox-Leyva L, Christensen C, et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000; 18: 1939-43.
75. Corny RM, Khazaeli MB, Saleh MN, et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5: 2330-7.
76. Chen D, Zuleger C, Chu Q, et al. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res Hum Retroviruses 2002; 18: 715-22.
77. Chen D, Periwal SB, Larrivee K, et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol 2001; 75: 7956-65.
78. Chen D, Endres RL, Erickson CA, et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000; 6: 1187-90.
79. Rogers WO, Baird JK, Kumar A, et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 2001; 69: 5565-72.
80. Manam S, Ledwith BJ, Barnum AB, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000; 43: 273-81.
81. Gramzinski RA, Millan CL, Obaldia N, et al. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998; 4: 109-18.
82. Degano P, Sarphie DF, Bangham CR. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 1998; 16: 394-8.
83. Zucchelli S, Capone S, Fattori E, et al. Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74: 11598-607.
84. Braun RP, Babiuk LA, Loehr BI, et al. Particle-mediated DNA immunization of cattle confers long-lasting immunity against bovine herpesvirus-1. Virology 1999; 265: 46-56.
85. Jankovic D, Liu Z, Gause WC. Th1-and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol 2001; 22: 450-7.
86. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2001; 53: 1-10.
87. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-14.
88. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
89. Selby M, Goldbeck C, Pertile T, et al. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83: 147-52.
90. Drabick JJ, Glasspool-Malone J, King A, et al. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 2001; 3: 249-55.
91. Glasspool-Malone J, Somiari S, Drabick JJ, et al. Efficient nonviral cutaneous transfection. Mol Ther 2000; 2: 140-6.
92. Babiuk S, Baca-Estrada M, Foldvari M, et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20: 3399.
93. Glasspool-Malone J, Steenland PR, McDonald RJ, et al. DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. J Gene Med 2002; 4: 323-32.
94. Glasspool-Malone J, Malone RW. Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields. Methods Enzymol 2002; 346: 72-91.
95. Shi Z, Curiel DT, Tang DC. DNA-based non-invasive vaccination onto the skin. Vaccine 1999; 17: 2136-41.
96. Liu LJ, Watabe S, Yang J, et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine 2001; 20: 42-8.
97. Watabe S, Xin KQ, Ihata A, et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 2001; 19: 4434-44.
98. Fan H, Lin Q, Morrissey GR, et al. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 1999; 17: 870-2.
99. Inoue T, Inoue Y, Hayashi K, et al. Topical administration of HSV gD-IL-2 DNA is highly protective against murine herpetic stromal keratitis. Cornea 2002; 21: 106-10.
100. Loehr BI, Willson P, Babiuk LA, et al. Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol 2000; 74: 6077-86.
101. Stevceva L, Abimiku AG, Franchini G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun 2000; 1: 308-15.
102. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996; 184: 1879-90.
103. Eo SK, Gierynska M, Kamar AA, et al. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 2001; 166: 5473-9.
104. McCluskie MJ, Weeratna RD, Payette PJ, et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002; 32: 179-85.
105. Etchart N, Buckland R, Liu MA, et al. Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997; 78: 1577-80.
106. Etchart N, Desmoulins PO, Chemin K, et al. Dendritic cells recruitment and in vivo priming of CD8+ CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein. J Immunol 2001; 167: 384-91.
107. Desvignes C, Etchart N, Kehren J, et al. Oral administration of hapten inhibits in vivo induction of specific cytotoxic CD8+ T cells mediating tissue inflammation: a role for regulatory CD4+ T cells. J Immunol 2000; 164: 2515-22.
108. Eriksson K, Ahlfors E, George-Chandy A, et al. Antigen presentation in the murine oral epithelium. Immunology 1996; 88: 147-52.
109. McCluskie MJ, Brazolot Millan CL, Gramzinski RA, et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999; 5: 287-300.
110. Sigel MB, Sinha YN, VanderLaan WP. Production of antibodies by inoculation into lymph nodes. Methods Enzymol 1983; 93: 3-12.
111. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001; 98: 3299-303.
112. Gretz JE, Norbury CC, Anderson AO, et al. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits, while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 2000; 192: 1425-40.
113. Gregoriadis G, Bacon A, Caparros-Wanderley W, et al. A role for liposomes in genetic vaccination. Vaccine 2002; 20 Suppl 5: B1-9.
114. Jones DH, Corns S, McDonald S, et al. Poly(DL-lactide-co-glycolide)- encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997; 15: 814-7.
115. Briones M, Singh M, Ugozzoli M, et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 2001; 18: 709-12.
116. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000; 7: 2105-12.
117. Cui Z, Mumper RJ. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 2002; 19: 939-46.
118. Cui Z, Mumper RJ. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int J Pharm 2002; 238: 229-39.
119. Cui Z, Mumper RJ. Topical immunization using nanoengineered genetic vaccines. J Control Release 2002; 81: 173-84.
120. Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release 2001; 75: 409-19.
121. Lim YB, Kim SM, Suh H, et al. Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier. Bioconjug Chem 2002; 13: 952-7.
122. Mittal SK, Aggarwal N, Sailaja G, et al. Immunization with DNA, adenovirus, or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 2000; 19: 253-63.
123. Mutwiri G, Bowersock T, Kidane A, et al. Induction of mucosal immune responses following enteric immunization with antigen delivered in alginate microspheres. Vet Immunol Immunopathol 2002; 87: 269-76.
124. Graff A, Sauer M, Van Gelder P, et al. Virus-assisted loading of polymer nanocontainer. Proc Natl Acad Sci USA 2002; 99: 5064-8.
125. Ross GF, Bruno MD, Uyeda M, et al. Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor. Gene Ther 1998; 5: 1244-50.
126. Hallick RB, Chelm BK, Gray PW, et al. Use of aurintricarboxylic acid as an inhibitor of nucleases during nucleic acid isolation. Nucleic Acids Res 1977; 4: 3055-64.
127. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21: 247-57.
128. Finlay BB, Cossart P. Exploitation of mammalian host cell functions by bacterial pathogens. Science 1997; 276: 718-25.
129. Paglia P, Medina E, Arioli I, et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998; 92: 3172-6.
130. Kaufmann SH. Immunity to intracellular bacteria. Annu Rev Immunol 1993; 11: 129-63.
131. Gentschev I, Mollenkopf H, Sokolovic Z, et al. Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 1996; 179: 133-40.
132. Gentschev I, Glaser I, Goebel W, et al. Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle. Infect Immun 1998; 66: 2060-4.
133. Hess J, Grode L, Gentschev I, et al. Secretion of different listeriolysin cognates by recombinant attenuated Salmonella typhimurium: superior efficacy of haemolytic over non-haemolytic constructs after oral vaccination. Microbes Infect 2000; 2: 1799-806.
134. Shata MT, Stevceva L, Agwale S, et al. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000; 6: 66-71.
135. Dietrich G, Bubert A, Gentschev I, et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol 1998; 16: 181-5.
136. Gentschev I, Dietrich G, Spreng S, et al. Delivery of protein antigens and DNA by attenuated intracellular bacteria. Int J Med Microbiol 2002; 291: 577-82.
137. Shiau AL, Chen YL, Liao CY, et al. Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine 2001; 19: 3947-56.
138. Darji A, zur Lage S, Garbe AI, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol 2000; 27: 341-9.
139. Brunham RC, Zhang D. Transgene as vaccine for chlamydia. Am Heart J 1999; 138: S519-22.
140. Al-Mariri A, Tibor A, Lestrate P, et al. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun 2002; 70: 1915-23.
141. Loser P, Huser A, Hillgenberg M, et al. Advances in the development of non-human viral DNA-vectors for gene delivery. Curr Gene Ther 2002; 2: 161-71.
142. Chaplin PJ, De Rose R, Boyle JS, et al. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun 1999; 67: 6434-8.
143. Manoj S, Griebel PJ, Babiuk LA, et al. Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep. J Immunol 2003; 170: 989-96.
144. Drew DR, Boyle JS, Lew AM, et al. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep. Vaccine 2001; 19: 4417-28.
145. Dean HJ, Terhune SS, Shieh MT, et al. Single amino acid substitutions in gD of herpes simplex virus 1 confer resistance to gD-mediated interference and cause cell-type-dependent alterations in infectivity. Virology 1994; 199: 67-80.
146. Smahel M, Sima P, Ludvikova V, et al. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001; 281: 231-8.
147. Prodinger WM. Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping. Immunol Res 1999; 20: 187-94.
148. Nielsen CH, Fischer EM, Leslie RG. The role of complement in the acquired immune response. Immunology 2000; 100: 4-12.
149. Suradhat S, Braun RP, Lewis PJ, et al. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 2001; 83: 79-92.
150. Green TD, Newton BR, Rota PA, et al. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001; 20: 242-8.
151. Ross TM, Xu Y, Green TD, et al. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001; 17: 829-35.
152. Fanslow WC, Srinivasan S, Paxton R, et al. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 1994; 6: 267-78.
153. Maxwell JR, Campbell JD, Kim CH, et al. CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J Immunol 1999; 162: 2024-34.
154. Frleta D, Demian D, Wade WF. Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo. Int Immunopharmacol 2001; 1: 265-75.
155. Koch N, van Driel IR, Gleeson PA. Hijacking a chaperone: manipulation of the MHC class II presentation pathway. Immunol Today 2000; 21: 546-50.
156. Rodriguez F, Harkins S, Redwine JM, et al. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol 2001; 75: 10421-30.
157. Leifert JA, Lindencrona JA, Charo J, et al. Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine. Hum Gene Ther 2001; 12: 1881-92.
158. Fu TM, Guan L, Friedman A, et al. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine 1998; 16: 1711-7.
159. Leachman SA, Shylankevich M, Slade MD, et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002; 76: 7616-24.
160. Delogu G, Howard A, Collins FM, et al. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000; 68: 3097-102.
161. Vidalin O, Tanaka E, Spengler U, et al. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 1999; 18: 611-21.
162. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-3.
163. Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6: 12-21.
164. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33.
165. Harms JS, Ren X, Oliveira SC, et al. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations. J Virol 2000; 74: 3301-12.
166. Hung CF, He L, Juang J, et al. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002; 76: 2676-82.
167. Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-40.
168. Michel N, Osen W, Gissmann L, et al. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002; 294: 47-59.
169. Oliveira SC, Harms JS, Afonso RR, et al. A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum Gene Ther 2001; 12: 1353-9.
170. Aints A, Dilber MS, Smith CI. Intercellular spread of GFP-VP22. J Gene Med 1999; 1: 275-9.
171. Cheng WF, Hung CH, Chai CY, et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 2001; 75: 2368-76.
172. Zinkemagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001; 293: 251-3.
173. Yu Z, Karem KL, Kanangat S, et al. Protection by minigenes: a novel approach of DNA vaccines. Vaccine 1998; 16: 1660-7.
174. Kedl RM, Rees WA, Hildeman DA, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000; 192: 1105-13.
175. Restifo NP, Bacik I, Irvine KR, et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 1995; 154: 4414-22.
176. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-56.
177. Kusakabe K, Xin KQ, Katoh H, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102-11.
178. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161: 1875-82.
179. Pulendran B, Smith JL, Caspary G, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999; 96: 1036-41.
180. Lim YS, Kang BY, Kim EJ, et al. Vaccination with an ovalbumin/ interleukin-4 fusion DNA efficiently induces Th2 cell-mediated immune responses in an ovalbumin-specific manner. Arch Pharm Res 1998; 21: 537-42.
181. Inoue T, Inoue Y, Nakamura T, et al. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis. Jpn J Ophthalmol 2002; 46: 370-76.
182. Landolfi NF. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J Immunol 1991; 146: 915-9.
183. Kim JJ, Ayyavoo V, Bagarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-26.
184. Kim JJ, Nottingham LK, Tsai A, et al. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J Med Primatol 1999; 28: 214-23.
185. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129-35.
186. Xiang ZQ, He Z, Wang Y, et al. The effect of interferon-gamma on genetic
187. Tsuji T, Fukushima J, Hamajima K, et al. HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine. Immunology 1997; 90: 1-6.
188. Flo J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules. Immunology 2000; 100: 259-67.
189. Lee SW, Youn JW, Seong BL, et al. IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Vaccine 1999; 17: 490-6.
190. Okada E, Sasaki S, Ishii N, et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997; 159: 3638-47.
191. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-9.
192. Kim JJ, Trivedi NN, Nottingham LK, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28: 1089-103.
193. Arrington J, Braun RP, Dong L, et al. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 2002; 76: 4536-46.
194. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002; 4: 23-7.
195. Schneider J, Langermans JA, Gilbert SC, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001; 19: 4595-602.
196. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med 1999; 189: 701-10.
197. Rees W, Bender J, Teague TK, et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999; 96: 9781-6.
198. Bramson JL, Wan YH. The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin Biol Ther 2002; 2: 75-85.
199. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21: 163-5.
200. Palmowski MJ, Choi EM, Hermans JP, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168: 4391-8.
201. Letvin NL, Montefiori DC, Yasutomi Y, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997; 94: 9378-83.
202. Yuan R, Primakoff P, Myles DG. A role for the disintegrin domain of cyritestin, a sperm surface protein belonging to the ADAM family, in mouse sperm-egg plasma membrane adhesion and fusion. J Cell Biol 1997; 137: 105-12.
203. Jansen S, Ekhlasi-Hundrieser M, Topfer-Petersen E. Sperm adhesion molecules: structure and function. Cells Tissues Organs 2001; 168: 82-92.
204. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995; 377: 632-5.
205. Cooke H. Mammalian artificial chromosomes as vectors: progress and prospects. Cloning Stem Cells 2001; 3: 243-9.
206. Saffery R, Choo KH. Strategies for engineering human chromosomes with therapeutic potential. J Gene Med 2002; 4: 5-13.
207. Dufresne I, Desormeaux A, Bestman-Smith J, et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments. Biochim Biophys Acta 1999; 1421: 284-94.
208. Estrada A, McDermott MR, Underdown BJ, et al. Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine 1995; 13: 901-7.
209. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998; 392: 408-11.
210. You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001; 61: 3704-11.
211. Abbas AK, Lichtman AH, S. PJ. Antigen receptors and accessory molecules of T lymphocytes. In: Schmitt W, Hacker HN, Ehlers J, Eds. Cellular and Moleucular Immunology, 4th edition, pp. 102-21. Saunders Company, Philadelphia, 2000.
212. Epel M, Ellenhorn JD, Diamond DJ, et al. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol Immunother 2002; 51: 565-73.
213. Lunde E, Rasmussen IB, Eidem JK, et al. 'Troy-bodies': antibodies as vector proteins for T cell epitopes. Biomol Eng 2001; 18: 109-16.
214. Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002; 20: 1039-45.
215. Rothel JS, Boyle DB, Both GW, et al. Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep. Parasite Immunol 1997; 19: 221-7.
216. Hammond JM, Jansen ES, Morrissy CJ, et al. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Vet Microbiol 2001; 80: 101-19.
217. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331-5.
218. McShane H, Brookes R, Gilbert SC, et al. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 681-6.
219. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 4: 397-402.
220. Leong KH, Ramsay AJ, Boyle DB, et al. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994; 68: 8125-30.
221. Loehr BI, Pontarollo R, Rankin R, et al. Priming by DNA immunization augments T-cell responses induced by modified live bovine herpesvirus vaccine. J Gen Virol 2001; 82: 3035-43.
222. Webster DE, Cooney ML, Huang Z, et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol 2002; 76: 7910-2.
223. Moraes MP, Mayr GA, Mason PW, et al. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002; 20: 1631-9.
224. Hammond JM, Jansen ES, Morrissy CJ, et al. Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus. Vaccine 2001; 19: 3752-8.
225. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, et al. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 2001; 98: 11491-6.
226. Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3: 651-8.
227. Yoshida T, Okuda K, Xin KQ, et al. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin Exp Immunol 2001; 124: 445-52.
228. Meseda CA, Elkins KL, Merchlinsky MJ, et al. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 2002; 186: 1065-73.
229. Kaneko H, Bednarek I, Wierzbicki A, et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000; 267: 8-16.
230. Wild TF, Bernard A, Spehner D, et al. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J Gen Virol 1992; 73: 359-67.
231. Li S, Rodrigues M, Rodriguez D, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993; 90: 5214-8.
232. Earl PL, Wyatt LS, Montefiori DC, et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002; 294: 270-81.
233. Gilbert SC, Schneider J, Plebanski M, et al. Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; Comparisons and combinations. Biol Chem 1999; 380: 299-303.
234. Oliveira-Ferreira J, Miyahira Y, Layton GT, et al. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 2000; 18: 1863-9.
235. Nilsson C, Makitalo B, Berglund P, et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001; 19: 3526-36.